1234366-96-1

Usage

Uses

Used in Organic Synthesis:
1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanone is used as a building block in organic synthesis for the creation of more complex molecules. Its unique structure allows for various chemical reactions, making it a valuable component in the development of new compounds.
Used in Pharmaceutical Research:
In Pharmaceutical Research, 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanone is used as a starting material for the development of new drugs. Its potential applications in medicinal chemistry and drug development are being explored due to its distinctive structural features and properties.
Used in Medicinal Chemistry:
1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanone is utilized in medicinal chemistry for the design and synthesis of novel therapeutic agents. Its unique chemical structure may contribute to the development of innovative pharmaceuticals with improved efficacy and safety profiles.
Safety Precautions:
When handling 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanone, it is crucial to take safety precautions due to its potential hazards and toxic effects. Proper protective equipment, such as gloves and eye protection, should be worn, and the compound should be stored and used in accordance with established safety guidelines to minimize risks.

Upstream product

• 5013-77-4 N-methyl-N-(2,4-dichlorobenzyl)amine 
• 18523-22-3 2,3'-dibromoacetophenone 

Downstream Products

• 1234366-97-2 1-(3-bromophenyl)-2-((2,4-dichlorobenzyl)(methyl)amino)ethanol 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract